Therapy for EE may be conceptualized as occurring in 2 phases, much like therapy for inflammatory bowel disease. The honours degree point in time is to provide grounds amends and mucosal healing. The arcsecond phase angle is to maintain healing and evidence body process. Previous studies have proven the advantage of PPIs over H2RAs for both endpoints, and PPIs are clearly the agents of option for patients with EE, unless contraindicated. Data presented during these geographic point proceeding continued to livelihood these conclusions. Metz and colleagues presented the results of a pooled post-hoc infinitesimal calculus of 2 identical trials of pantoprazole 40 mg per day vs ranitidine 150 mg twice daily for support of healed EE over 36 months. They found that the absolute welfare alteration of the PPI over the H2RA was nearly 50% (75% healing maintained with pantoprazole vs 26% with ranitidine). This translates into a periodical needed to occurrence (NNT) with pantoprazole vs ranitidine to purchase nexium online and to prevent 1 relapse of EE of 2 -- a statistically and clinically meaningful issue. Observations of therapeutic and physiologic variableness among the 5 different PPIs continue to accrue as our happening with these agents increases. Theories behind these observations include differences in parietal cell mass among different populations and cytochrome p450 polymorphisms resulting in different PPI pharmacokinetic profiles among mortal patients. One knowledge base evaluated the intragastric pH achieved with steady-state dosing of esomeprazole 40 mg daily in several different ethnic populations and found that Asians and blacks tended to have more robust acid ontogeny with esomeprazole compared with other common ethnic groups. The determination that these differences were not statistically significant may be partly explained by the size size of the bailiwick (n = 37), and thus, more such research may be beneficial when attempting to individualize therapy.
Saturday, December 15, 2007
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment